| Number: 201108256 |
Principal Investigator: Saad, Nael |
| Title: Hepatic Arterial Embolization of Hepatocellular Carcinoma with a Doxorubicin Eluting Bead |
| ___________________________________________________________________________________________________ |
| Number: 201107319 |
Principal Investigator: Parikh, Parag |
| Title: Feasibility Study of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma |
| Description: This study is being done to
determine if targeted radiation therapy (stereotactic) can be given to treat liver cancer over a short period of time with a small amount of side effects. Conventional radiation therapy, which does not use this high level of targeting and often takes weeks to deliver, ha...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201104308 |
Principal Investigator: Chapman, William |
| Title: Clinical Application of Image-Guided Liver Surgery |
| Description: To use image-guided surgery for improvement of surgeon's ability to remove liver tumors....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201209059 |
Principal Investigator: Wagner-Johnston, Nina |
| Title: Multisite randomized controlled trial of continuing vs. discontinuing statins |
| Description: The purpose of this study is to determine if discontinuing statin medications is safe and can reduce the burden of taking numerous medications. We anticipate that people with advanced illness will have less medicine-related side effects and symptoms if statins are discontinued, better quality of lif...MORE |
| ___________________________________________________________________________________________________ |
| Number: CTSU E1208 |
Principal Investigator: Tan, Benjamin |
| Title: A Phase III Randomized, Double-Blind Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion |
| Description: The purpose of this study is to see if adding the oral chemotherapy pill, sorafenib (Nexavar), to localized chemotherapy (chemoembolization) to the liver will help patients to live longer than treatment with localized chemotherapy to the liver without sorafenib....MORE |
| ___________________________________________________________________________________________________ |
| Number: CALGB 80802 |
Principal Investigator: Tan, Benjamin |
| Title: Phase III randomized study of Sorafenib plus Doxorubicin versus Sorafenib in patients with Advanced Hepatocellular Carcinoma (HCC) |
| Description: The purpose of this study is to compare the effects (good and bad) of the drug sorafenib with the combination of sorafenib plus doxorubicin on patients and their advanced primary liver cancer to find out which is better....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201301150 |
Principal Investigator: Tan, Benjamin |
| Title: A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib |
| Description: The purpose of this study is to assess if regorafenib in combination with best supportive care is safe and will slow down the growth of tumor or even shrink the tumor and result in increased survival in patients who
experienced failure of previous sorafenib treatment....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201202001 |
Principal Investigator: Zuckerman, Darryl |
| Title: A Phase III Clinical Trial Evaluating TheraSphere in Patients with Metastatic Colorectal Carcinoma of the Liver who have Failed First Line Chemotherapy |
| Description: The purpose of this research study is to examine whether adding treatment with TheraSphere early in the current standard for second-line chemotherapy treatment of metastatic colorectal cancer is better
than the current treatment alone. Better means slowing or stopping the growth of liver tumors
...MORE |
| ___________________________________________________________________________________________________ |
| Number: ACRIN 6690 |
Principal Investigator: Menias, Christine |
| Title: A Prospective, Multicenter Comparison of Multiphase Contrast-Enhanced CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation |
| ___________________________________________________________________________________________________ |
| Number: 201110093 |
Principal Investigator: Chapman, William |
| Title: Human Hepatocyte Isoltaion Trial |
| ___________________________________________________________________________________________________ |
| Number: 201106049 |
Principal Investigator: Chapman, William |
| Title: The Hepatic Research Registry |
| ___________________________________________________________________________________________________ |
| Number: 201301098 |
Principal Investigator: Owen, Joseph |
| Title: A Revisit of Complete Radiologic Response of Colorectal Liver Metastases (Disappearing Lesions) in the Era of Eovist (Gadoxetate Disodium) |
| ___________________________________________________________________________________________________ |
| Number: 201104355 |
Principal Investigator: Brunt, Elizabeth |
| Title: Expression of glutamine synthetase in liver diseases |
| ___________________________________________________________________________________________________ |
| Number: 201108327 |
Principal Investigator: Wang-Gillam, Andrea |
| Title: Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies |
| Description: The purpose of this study is to determine the maximum tolerated dose and side effects of the combination of two drugs, temsirolimus and erlotinib, used to treat solid tumor cancers. Temsirolimus is approved by the Food and Drug Administration (FDA) for treatment of renal cancer and is considered inv...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201107068 |
Principal Investigator: Lockhart, A. Craig |
| Title: Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients with Varying Degrees of Hepatic Impairment |
| Description: The purpose of this study is to determine if Cabazitaxel is a safe treatment for patients with advanced cancers of different types who also have different levels of liver dysfunction. The highest safe dose of cabazitaxel (the maximum tolerated dose, or MTD) that can be given to patients with your le...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102468 |
Principal Investigator: Lockhart, A. Craig |
| Title: An Open-Label Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 When Administered as a Single Agent in Patients With
Advanced or Metastatic Solid Tumors |
| Description: There are two parts to this research study. The purpose of Part 1 is to find out the highest safe dose of the investigational drug CEP-9722. “Investigational” means that the study drug has not been approved by the United States Food & Drug Administration (F.D.A). Part 2 of the study is to find out m...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102462 |
Principal Investigator: Lockhart, A. Craig |
| Title: A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects with Advanced Solid Malignancies |
| Description: The main purpose of this study is to find out if the drug ZSTK474 is safe in people who have advanced cancers.
ZSTK474 is an investigational (experimental) drug. This means it has not been approved by the Food and Drug Administration (FDA). It is not currently on the market in any country. This stu...MORE |
| ___________________________________________________________________________________________________ |